Phase II study of pemetrexed and erlotinib in pretreated nonsquamous, non-small-cell lung cancer patients without an EGFR mutation
YH Kim, T Nishimura, H Ozasa, H Nagai, Y Sakamori… - Chemotherapy, 2014 - karger.com
Background: Preclinical data indicated that the combination of erlotinib and pemetrexed is
synergistic when erlotinib is administered after pemetrexed. Patients and Methods: This was …
synergistic when erlotinib is administered after pemetrexed. Patients and Methods: This was …
Randomized phase III trial of erlotinib versus docetaxel as second-or third-line therapy in patients with advanced non–small-cell lung cancer: Docetaxel and Erlotinib …
T Kawaguchi, M Ando, K Asami, Y Okano… - Journal of clinical …, 2014 - ascopubs.org
Purpose To investigate the efficacy of erlotinib versus docetaxel in previously treated
patients with advanced non–small-cell lung cancer (NSCLC) in an epidermal growth factor …
patients with advanced non–small-cell lung cancer (NSCLC) in an epidermal growth factor …
Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc …
Objectives Sequential combination of epidermal growth factor receptor (EGFR)-tyrosine
kinase inhibitors (TKIs) and chemotherapy has shown greater benefits than either treatment …
kinase inhibitors (TKIs) and chemotherapy has shown greater benefits than either treatment …
Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer
S Ricciardi, S Tomao, F de Marinis - Lung Cancer: Targets and …, 2010 - Taylor & Francis
Lung cancer is the leading cause of cancer deaths worldwide. Targeting the epidermal
growth factor receptor (EGFR) has played a central role in advancing non-small-cell lung …
growth factor receptor (EGFR) has played a central role in advancing non-small-cell lung …
Intercalated Dosing Schedule of Erlotinib and Docetaxel as a Therapeutic Strategy to Avoid Antagonism and Optimize Its Benefits in Advanced Non–Small-Cell Lung …
Ó Juan, F Aparisi, A Sánchez-Hernández… - Clinical Lung Cancer, 2015 - Elsevier
Introduction The purpose of this study was to assess whether an intercalated dosing
schedule of erlotinib and docetaxel could avoid possible negative interactions and optimize …
schedule of erlotinib and docetaxel could avoid possible negative interactions and optimize …
Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC)
M Faehling, J Achenbach, P Staib, U Steffen… - Journal of Cancer …, 2018 - Springer
Purpose The controlled phase III trial SATURN demonstrated that maintenance therapy with
erlotinib after the first-line platinum-based chemotherapy prolonged progression-free …
erlotinib after the first-line platinum-based chemotherapy prolonged progression-free …
Erlotinib in previously treated non–small-cell lung cancer
FA Shepherd, J Rodrigues Pereira… - New England journal …, 2005 - Mass Medical Soc
Background We conducted a randomized, placebo-controlled, double-blind trial to
determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival …
determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival …
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
SM Lee, I Khan, S Upadhyay, C Lewanski… - The lancet …, 2012 - thelancet.com
Background Many patients with advanced non-small-cell lung cancer (NSCLC) receive only
active supportive care because of poor performance status or presence of several …
active supportive care because of poor performance status or presence of several …
International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by …
C Gridelli, F Ciardiello, R Feld, CA Butts… - Journal of Clinical …, 2010 - ascopubs.org
7508 Background: In a placebo-controlled trial, E prolonged survival of unselected aNSCLC
patients (pts) not eligible for further chemotherapy. Two phase II studies suggested that first …
patients (pts) not eligible for further chemotherapy. Two phase II studies suggested that first …
Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
RGP Gijtenbeek, V van der Noort… - ERJ Open …, 2022 - Eur Respiratory Soc
Introduction Previous studies have shown interference between epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors and chemotherapy in the cell cycle, thus reducing …
receptor (EGFR) tyrosine kinase inhibitors and chemotherapy in the cell cycle, thus reducing …